Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention

Journal of the American Society of Nephrology

Volumn 22, Issue 4, 2011, Pages 627-633

  Htun, Patrik ^a   Fateh Moghadam, Suzanne ^a   Bischofs, Christian ^a   Banya, Winston ^b   Müller, Karin ^a   Bigalke, Boris ^a   Stellos, Konstantinos ^a   May, Andreas E ^a   Flather, Marcus ^b   Gawaz, Meinrad ^a   Geisler, Tobias ^a,b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DEATH; DRUG EFFECT; DRUG RESPONSE; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SURVIVAL; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE;

EID: 79953296443     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010020220     Document Type: Article

References (42)

1. Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, Herdeg C, Gawaz M: The PREDICT (Residual Platelet Aggregation after Deployment of Intracoronary Stent)-Score. J Thromb Haemost 6: 54-61, 2008
2. Geisler T, Zürn C, Simonenko R, Rapin M, Kraibooj H, Kilias A, Bigalke B, Stellos K, Schwab M, May AE, Herdeg C, Gawaz M: Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 31: 59-66, 2010
3. Latif F, Kleiman NS, Cohen DJ, Pencina MJ, Yen CH, Cutlip DE, Moliterno DJ, Nassif D, Lopez JJ, Saucedo JF, EVENT Investigators: In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv 2: 37-45, 2009
4. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, Kim SW, Bui A, Gevorkian N, Xue Z, Smith K, Fournadjieva J, Suddath WO, Satler LF, Pichard AD, Kent KM, Waksman R: Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113: 1108-1113, 2006
5. Jacques M, Nicolas D, Jean ML, Jean MF, Jean LB, Stephanie M, Alison F, Jean LQ, Hélène E, Gérald V: Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients. J Am Coll Cardiol 50: 501-508, 2007
6. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293: 2126-2130, 2005 (Pubitemid 40617065)
7. Deray G, Bagnis C, Brouard R, Necciari J, Leenhardt AF, Raymond F, Baumelou A: Clopidogrel activities in patients with renal function impairment. Clin Drug Investig 16: 319-328, 1998 (Pubitemid 28499438)
8. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS: Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29: 992-1000, 2008 (Pubitemid 351844676)
9. Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W: A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 104: 1292-1295, 2009
10. Naidu SS, Selzer F, Jacobs A, Faxon D, Marks DS, Johnston J, Detre K, Wilensky RL: Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention. Am J Cardiol 92: 1160-1164, 2003 (Pubitemid 37377824)
11. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB: The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 39: 1113-1119, 2002 (Pubitemid 34267412)
12. Blackman DJ, Pinto R, Ross JR, Seidelin PH, Ing D, Jackevicius C, Mackie K, Chan C, Dzavik V: Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. Am Heart J 151: 146-152, 2006 (Pubitemid 41815345)
13. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
14. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, Fahy M, Cox DA, Garcia E, Tcheng JE: Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 108: 2769-2775, 2003 (Pubitemid 37498979)
15. Cardarelli F, Bellasi A, Ou FS, Shaw LJ, Veledar E, Roe MT, Morris DC, Peterson ED, Klein LW, Raggi P: Combined impact of age and estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry). Am J Cardiol 103: 766-771, 2009
16. Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, Califf RM, Topol EJ; CREDO Investigators: The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 155: 687-693, 2008
17. Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, Fox KA, Montalescot G, Weber MA, Haffner SM, Dimas AP, Steg PG, Topol EJ; CHARISMA Investigators: Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol 103: 1359-1363, 2009
18. Himmelfarb J, Holbrook D, McMonagle E, Ault K: Increased reticulated platelets in dialysis patients. Kidney Int 51: 834-839, 1997 (Pubitemid 27157970)
19. Linthorst GE, Folman CC, van Olden RW, von dem Borne AE: Plasma thrombopoietin levels in patients with chronic renal failure. Hematol J 3: 38-42, 2002 (Pubitemid 34223914)
20. Gawaz MP, Ward RA. Effects of hemodialysis on platelet-derived thrombospondin: Kidney Int 40: 257-265, 1991
21. Touchette MA, Slaughter RL: The effect of renal failure on hepatic drug clearance. DICP 25: 1214-1224, 1991
22. Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V: Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12: 326-332, 2001 (Pubitemid 32116374)
23. Sagripanti A, Cupisti A, Baicchi U, Ferdeghini M, Morelli E, Barsotti G: Plasma parameters of the prothrombotic state in chronic uremia. Nephron 63: 273-278, 1993 (Pubitemid 23082067)
24. Irish A: Cardiovascular disease, fibrinogen and the acute phase response: Associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 137: 133-139, 1998
25. Remuzzi G, Cavernaghi AE, Mecca G, Donati MB, de Gaetano G: Prostacyclin like activity and bleeding in renal failure. Lancet 2: 1195-1197, 1977 (Pubitemid 8237196)
26. Gawaz MP, Dobos G, Späth M, Schollmeyer P, Gurland HJ, Mujais SK: Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 5: 36-46, 1994 (Pubitemid 24977057)
27. Ballow A, Gader AM, Huraib S, Al-Husaini K, Mutwalli A, Al-Wakeel J: Platelet surface receptor activation in patients with chronic renal failure on hemodialysis, peritoneal dialysis and those with successful kidney transplantation. Platelets 16: 19-24, 2005 (Pubitemid 40115942)
28. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, Gorman J, Taylor DW: Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 4: 1809-1813, 1994
29. Noris M, Benigni A, Boccardo P: Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension. Kidney Int 44: 445-450, 1993 (Pubitemid 23228703)
30. Russo D, Palmiero G, De Blasio AP, Balletta MM, Andreucci VE: Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 44: 1024-1030, 2004 (Pubitemid 39556482)
31. Dellegrottaglie S, Saran R, Gillespie B, Zhang X, Chung S, Finkelstein F, Kiser M, Sanz J, Eisele G, Hinderliter AL, Kuhlmann M, Levin NW, Rajagopalan S: Prevalence and predictors of cardiovascular calcium in chronic kidney disease (from the Prospective Longitudinal RRI-CKD Study). Am J Cardiol 98: 571-576, 2006 (Pubitemid 44233449)
32. Arad Y, Goodman K, Roth M, Newstein D, Guerci AD: Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: The St. Francis Heart Study J Am Coll Cardiol 46: 158-165, 2005 (Pubitemid 40905145)
33. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M, Bluemke DA, O'Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA: Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 358: 1336-1345, 2008 (Pubitemid 351468410)
34. Attallah N, Yassine L, Fisher K, Yee J: Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. Clin Nephrol 64: 412-418, 2005 (Pubitemid 41819400)
35. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39: S1-S266, 2002
36. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139: 137-147, 2003
37. Müller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schömig A, Gawaz M: Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85: 92-93, 2001 (Pubitemid 32973418)
38. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Büttner HJ, Neumann FJ: Time Dependence of Platelet Inhibition after a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention Circulation 111: 2560-2564, 2005
39. Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A: Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost 80: 994-1001, 1998 (Pubitemid 28556705)
40. Neumann FJ, Hochholzer W, Pogatsa-Murray G, Schomig A, Gawaz M: Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 37: 1323-1328, 2001
41. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Büttner HJ, Neumann FJ: Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48: 1742-1750, 2006 (Pubitemid 44648629)
42. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109: 3171-3175, 2004